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Introduction: Phenytoin, phenobarbital and valproic acid are anti-epileptic drugs, frequently 
used in clinical practice. Because of high protein binding, narrow therapeutic range and 
variable bioavailability, monitoring might be useful. Vancomycin is a glycopeptide antibiotic. 
Appropriate dosing depends on patient variables (weight, renal function, …) and 
susceptibility of the pathogen, therefore monitoring is necessary. We evaluated the analytical 
performance of the Abbott Architect™ assays for monitoring these drugs. All parameters are 
measured in serum/plasma. 
Methods: Accuracy and between-run precision were evaluated based on at least 10 
measurements of Abbott Immunoassay-MCC liquid controls (3 levels). Except for valproic 
acid (n=10), evaluation of within-run precision was calculated by analysing control material 6 
times in one run. For all parameters a method comparison with the currently used routine 
method was performed (Abbott Axsym™). 
Results and discussion: At 6.7-23.5 µg/mL phenytoin, bias (n=10) varied between -0.2 and 
1.1%; between (n=10) and within-run CV ranges 2.4-2.6% and 1.6-2.4% respectively.  At 
10.4-51.3 µg/mL phenobarbital, bias (n=12) varied between 2.8% and 8.5%; between (n=12) 
and within-run CV ranges 1.8-3.8% and 1.4-2.5% respectively. At 41.6-133 µg/mL valproic 
acid, bias (n=22) varied between -2.9 and 0.5% and between-run CV (n=22) ranges 3.5-
4.0%. At 41.8 µg/mL within-run CV is 2.8%. At 7.1-32.5 µg/mL vancomycin, bias (n=11) 
varied between 0.3-1.3%; between (n=11) and within-run CV ranges 1.9-2.5% and 1.2-2.1% 
respectively. 
Method comparison for phenytoin (n=42) showed that a 12.4% lower result could be 
expected compared to Axsym™. For phenobarbital (n=34) a 9.9% higher result was obtained 
compared to Axsym™. For valproic acid a 7.4% and 0.1% higher result was observed 
compared to Axsym™ for comparison of frozen (n=24) and fresh (n=46) samples 
respectively. For vancomycin (n=40) a 12.9% higher result was observed compared to 
Axsym™.  
Overall, the analytical performance of the Abbott Architect™ assays is satisfactory. Accuracy 
and precision are comparable to or better than the currently used methods. Differences 
found in the method comparison were not considered significant based on an allowable error 
of 24%. The method comparison for phenytoin, Phenobarbital, valproic acid and vancomycin 
was performed on frozen samples and showed higher results on Architect™ compared to 
Axsym™. Method comparison for valproic acid was also performed on fresh samples and 
shows no bias between both methods. Freezing of samples might contribute to the observed 
differences between both methods. Reference values were not adapted. 
